[go: up one dir, main page]

CA2756581A1 - Nanosystemes lies a l'ascorbate pour administration cerebrale - Google Patents

Nanosystemes lies a l'ascorbate pour administration cerebrale Download PDF

Info

Publication number
CA2756581A1
CA2756581A1 CA2756581A CA2756581A CA2756581A1 CA 2756581 A1 CA2756581 A1 CA 2756581A1 CA 2756581 A CA2756581 A CA 2756581A CA 2756581 A CA2756581 A CA 2756581A CA 2756581 A1 CA2756581 A1 CA 2756581A1
Authority
CA
Canada
Prior art keywords
ascorbate
liposome
micelle
brain
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2756581A
Other languages
English (en)
Inventor
Vladimir Torchilin
Tiziana Musacchio
Stefano Salmaso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita degli Studi di Padova
Northeastern University Boston
Original Assignee
Universita degli Studi di Padova
Northeastern University Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita degli Studi di Padova, Northeastern University Boston filed Critical Universita degli Studi di Padova
Publication of CA2756581A1 publication Critical patent/CA2756581A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2756581A 2009-03-26 2010-03-26 Nanosystemes lies a l'ascorbate pour administration cerebrale Abandoned CA2756581A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16357709P 2009-03-26 2009-03-26
US61/163,577 2009-03-26
PCT/US2010/028872 WO2010111620A1 (fr) 2009-03-26 2010-03-26 Nanosystèmes liés à l'ascorbate pour administration cérébrale

Publications (1)

Publication Number Publication Date
CA2756581A1 true CA2756581A1 (fr) 2010-09-30

Family

ID=42781556

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2756581A Abandoned CA2756581A1 (fr) 2009-03-26 2010-03-26 Nanosystemes lies a l'ascorbate pour administration cerebrale

Country Status (5)

Country Link
EP (1) EP2410992A4 (fr)
CN (1) CN102458365A (fr)
AU (1) AU2010229700A1 (fr)
CA (1) CA2756581A1 (fr)
WO (1) WO2010111620A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372250B1 (en) * 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US20080279764A1 (en) * 2007-03-09 2008-11-13 Anthony Manganaro Method and composition for treating cancer

Also Published As

Publication number Publication date
AU2010229700A1 (en) 2011-10-27
EP2410992A1 (fr) 2012-02-01
WO2010111620A1 (fr) 2010-09-30
EP2410992A4 (fr) 2013-09-11
CN102458365A (zh) 2012-05-16

Similar Documents

Publication Publication Date Title
US11701432B2 (en) Polyglutamated antifolates and uses thereof
US20250066468A1 (en) Liposome encapsulated affinity drug
US12296022B2 (en) D glutamate polyglutamated antifolates and uses thereof
US9655848B2 (en) Liposomes for in-vivo delivery
US20110190623A1 (en) Thermally-activatable liposome compositions and methods for imaging, diagnosis and therapy
WO2020232701A1 (fr) Système d'administration de médicament à nanoliposome marqué par un monosaccharide, sa méthode de préparation et son utilisation en tant que vecteur d'administration de ciblage pour un médicament
WO2022242762A1 (fr) Application d'une composition pharmaceutique ayant un rapport médicament-lipide spécifique en anti-tumoral
CA2756581A1 (fr) Nanosystemes lies a l'ascorbate pour administration cerebrale
US20240033374A1 (en) Nano-structural Protein Degradation Tool, Use, and Preparation Method thereof, and Lipid-based Protein Degradation Tool, Use, and Preparation Method thereof
CN121177507A (zh) α和γ-D聚谷氨酸化抗叶酸剂及其用途
BR112019002495B1 (pt) Composição lipossomal peguilada de antifolatos poliglutamatados, seu uso e método de preparação
OA19187A (en) Polyglutamated antifolates and uses thereof.

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20160329